全球藥物基因組學技術市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

全球藥物基因組學技術市場需求預計將從 2022 年的 76 億美元增至 2030 年近 155.9 億美元，2023-2030 年研究期間CAGR為 9.4%。

藥物基因組學技術通常縮寫為PGx，是一個跨學科領域，它將藥物研究（即藥理學）和基因及其功能研究（即基因組學）結合起來，以了解個體的基因組成如何影響其對藥物的反應。該領域旨在根據個體的基因譜定製藥物治療，最終實現更有效、更安全的藥物治療。

市場動態：

在多種因素的推動下，藥物基因組學技術市場正在經歷大幅成長，這些因素強調了遺傳學在醫療保健中的關鍵作用以及更有效和個人化治療的潛力。藥物基因組學根據個體的基因譜定製藥物治療，處於醫學變革的最前沿。基因組研究的進步以及與藥物反應相關的遺傳標記的識別正在擴展藥物基因組學技術的能力。隨著醫療保健提供者和製藥公司越來越重視藥物的安全性和有效性，藥物基因組學透過識別有不良反應風險的患者並最佳化藥物選擇和劑量，提供了有價值的解決方案。個人化醫療的興起，特別是在腫瘤學領域，是一個重要的推動因素，可以根據患者的基因組成製定量身定做的治療計劃。政府措施、精準醫療計劃和患者倡導正在進一步促進藥物基因組學融入臨床實踐。倫理考量和負責任的遺傳資料被用來強調藥物基因組學技術提供更安全、更有效的醫療保健的必要性。製藥業在該領域的研發投資以及基因檢測技術的日益普及促進了市場的快速擴張。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球藥物基因組學技術市場的各個細分市場進行了包容性評估。藥物基因組學技術產業的成長和趨勢為這項研究提供了一種整體方法。

區域分析：

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲藥物基因組技術市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。藥物基因組學技術市場的主要參與者包括 QIAGEN、GE HealthCare、Agilent Technologies, Inc.、F. Hoffmann-La Roche Ltd、FOUNDATION MEDICINE, INC.、Thermo Fisher Scientific Inc.、Leica Biosystems Nussloch GmBH、Pfizer Inc.。包括對競爭格局的整體看法，包括各種策略發展，例如關鍵併購、未來能力、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第 1 章：前言

• 報告說明
  • 客觀的
  • 目標受眾
  • 獨特的銷售主張 (USP) 和產品
• 研究範圍
• 研究方法論
  • 市場研究過程
  • 市場研究方法論

第 2 章：執行摘要

• 市場亮點
• 全球市場概況

第 3 章：藥物基因體學技術 - 產業分析

• 簡介 - 市場動態
• 市場促進因素
• 市場限制
• 機會
• 產業動態
• 波特五力分析
• 市場吸引力分析
  • 按治療領域分類的市場吸引力分析
  • 按技術分類的市場吸引力分析
  • 市場吸引力分析：按地區

第 4 章：價值鏈分析

• 價值鏈分析
• 原料分析
  • 原料清單
  • 原料廠商清單
  • 主要原物料價格走勢
• 潛在買家名單
• 行銷管道
  • 直效行銷
  • 間接行銷
  • 行銷通路發展趨勢

第 5 章：全球藥物基因組學技術市場分析：按治療領域

• 按治療領域概述
• 歷史和預測數據
• 按治療領域分析
• 腫瘤學（肺癌、乳癌、大腸癌、子宮頸癌、其他）
• 神經系統疾病
• 心血管疾病
• 免疫系統疾病
• 傳染性疾病
• 其他

第 6 章：全球藥物基因組學技術市場分析：按技術分類

• 依技術概述
• 歷史和預測數據
• 依技術分析
• 聚合酶鍊式反應
• 原位雜合技術
• 免疫組織化學
• 定序
• 其他

第 7 章：全球藥物基因組學技術市場分析：按地理位置

• 區域展望
• 介紹
• 北美銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 北美按細分市場銷售分析
  • 北美按國家銷售分析
  • 美國銷售分析
  • 加拿大銷售分析
  • 墨西哥銷售分析
• 歐洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 歐洲按細分市場銷售分析
  • 歐洲按國家銷售分析
  • 英國銷售分析
  • 法國銷售分析
  • 德國銷售分析
  • 義大利銷售分析
  • 俄羅斯銷售分析
  • 歐洲其他地區銷售分析
• 亞太地區銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 亞太地區按細分市場銷售分析
  • 亞太地區國家/地區銷售分析
  • 中國銷售分析
  • 印度銷售分析
  • 日本銷售分析
  • 韓國銷售分析
  • 澳洲銷售分析
  • 東南亞銷售分析
  • 亞太地區其他地區銷售分析
• 拉丁美洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 拉丁美洲按細分市場銷售分析
  • 拉丁美洲按國家銷售分析
  • 巴西銷售分析
  • 阿根廷銷售分析
  • 秘魯銷售分析
  • 智利銷售分析
  • 拉丁美洲其他地區銷售分析
• 中東和非洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 中東和非洲按細分市場銷售分析
  • 中東和非洲國家銷售分析
  • 沙烏地阿拉伯銷售分析
  • 阿拉伯聯合大公國銷售分析
  • 以色列銷售分析
  • 南非銷售分析
  • 中東其他地區和非洲銷售分析

第 8 章：藥物基因體學技術公司的競爭格局

• 藥物基因組學技術市場競爭
• 夥伴關係/協作/協議
• 併購
• 新產品發布
• 其他發展

第 9 章：公司簡介

• 頂級公司市佔率分析
• 市場集中度
• QIAGEN
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• GE HealthCare
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Agilent Technologies Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• F. Hoffmann-La Roche Ltd.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• FOUNDATION MEDICINE INC.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Thermo Fisher Scientific Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Leica Biosystems Nussloch GmBH
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Pfizer Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

The global demand for Pharmacogenomics Technology Market is presumed to reach the market size of nearly USD 15.59 BN by 2030 from USD 7.6 BN in 2022 with a CAGR of 9.4% under the study period 2023 - 2030.

Pharmacogenomics technology, often abbreviated as PGx, is an interdisciplinary field that combines the study of drugs, i.e., pharmacology, and the study of genes and their functions, i.e., genomics, to understand how an individual's genetic makeup influences their response to medications. This field aims to tailor drug therapies to an individual's genetic profile, ultimately leading to more effective and safer drug treatments.

MARKET DYNAMICS:

The Pharmacogenomics technology market is experiencing substantial growth driven by a convergence of factors emphasizing the pivotal role of genetics in healthcare and the potential for more effective and personalized treatments. Pharmacogenomics, which tailors drug therapies to an individual's genetic profile, is at the forefront of this transformation in medicine. Advancements in genomic research and the identification of genetic markers associated with drug responses are expanding the capabilities of pharmacogenomics technology. As healthcare providers and pharmaceutical companies increasingly prioritize drug safety and efficacy, pharmacogenomics offers a valuable solution by identifying patients at risk of adverse reactions and optimizing drug selection and dosing. The rise of personalized medicine, particularly in oncology, is a significant driver, enabling tailored treatment plans based on a patient's genetic makeup. Government initiatives, precision medicine programs, and patient advocacy are further promoting the integration of pharmacogenomics into clinical practice. Ethical considerations and responsible genetic data are used to highlight the need for pharmacogenomics technology to provide safer and more effective healthcare. The Pharmaceutical industry's investment in research and development in this field and the increasing accessibility of genetic testing technology contribute to the market's rapid expansion.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of pharmacogenomics technology. The growth and trends of pharmacogenomics technology industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the pharmacogenomics technology market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Therapeutic Area

• Oncology (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others)
• Neurological Disorders
• Cardiovascular Disease
• Immunological Disorders
• Infectious Diseases
• Others

By Technology

• PCR
• In-Situ Hybridization
• Immunohistochemistry
• Sequencing
• Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Pharmacogenomics Technology market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Pharmacogenomics Technology market include QIAGEN, GE HealthCare, Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd, FOUNDATION MEDICINE, INC., Thermo Fisher Scientific Inc., Leica Biosystems Nussloch GmBH, Pfizer Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . PHARMACOGENOMICS TECHNOLOGY - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Therapeutic Area
  • 3.7.2 Market Attractiveness Analysis By Technology
  • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PHARMACOGENOMICS TECHNOLOGY MARKET ANALYSIS BY THERAPEUTIC AREA

• 5.1 Overview by Therapeutic Area
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Therapeutic Area
• 5.4 Oncology (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others) Historic and Forecast Sales by Regions
• 5.5 Neurological Disorders Historic and Forecast Sales by Regions
• 5.6 Cardiovascular Disease Historic and Forecast Sales by Regions
• 5.7 Immunological Disorders Historic and Forecast Sales by Regions
• 5.8 Infectious Diseases Historic and Forecast Sales by Regions
• 5.9 Others Historic and Forecast Sales by Regions

6 . GLOBAL PHARMACOGENOMICS TECHNOLOGY MARKET ANALYSIS BY TECHNOLOGY

• 6.1 Overview by Technology
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Technology
• 6.4 PCR Historic and Forecast Sales by Regions
• 6.5 In-Situ Hybridization Historic and Forecast Sales by Regions
• 6.6 Immunohistochemistry Historic and Forecast Sales by Regions
• 6.7 Sequencing Historic and Forecast Sales by Regions
• 6.8 Others Historic and Forecast Sales by Regions

7 . GLOBAL PHARMACOGENOMICS TECHNOLOGY MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. South East Asia Sales Analysis
  • 7.5.10. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE PHARMACOGENOMICS TECHNOLOGY COMPANIES

• 8.1. Pharmacogenomics Technology Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF PHARMACOGENOMICS TECHNOLOGY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. QIAGEN
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. GE HealthCare
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. Agilent Technologies Inc.
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. F. Hoffmann-La Roche Ltd.
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. FOUNDATION MEDICINE INC.
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments
• 9.8. Thermo Fisher Scientific Inc.
  • 9.8.1. Company Overview
  • 9.8.2. Company Revenue
  • 9.8.3. Products
  • 9.8.4. Recent Developments
• 9.9. Leica Biosystems Nussloch GmBH
  • 9.9.1. Company Overview
  • 9.9.2. Company Revenue
  • 9.9.3. Products
  • 9.9.4. Recent Developments
• 9.10. Pfizer Inc.
  • 9.10.1. Company Overview
  • 9.10.2. Company Revenue
  • 9.10.3. Products
  • 9.10.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Therapeutic Area (USD MN)
• Oncology (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others) Market Sales by Geography (USD MN)
• Neurological Disorders Market Sales by Geography (USD MN)
• Cardiovascular Disease Market Sales by Geography (USD MN)
• Immunological Disorders Market Sales by Geography (USD MN)
• Infectious Diseases Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis Market by Technology (USD MN)
• PCR Market Sales by Geography (USD MN)
• In-Situ Hybridization Market Sales by Geography (USD MN)
• Immunohistochemistry Market Sales by Geography (USD MN)
• Sequencing Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Pharmacogenomics Technology Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Pharmacogenomics Technology Report
• Market Research Process
• Market Research Methodology
• Global Pharmacogenomics Technology Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Therapeutic Area
• Market Attractiveness Analysis by Technology
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Therapeutic Area (USD MN)
• Oncology (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others) Market Sales by Geography (USD MN)
• Neurological Disorders Market Sales by Geography (USD MN)
• Cardiovascular Disease Market Sales by Geography (USD MN)
• Immunological Disorders Market Sales by Geography (USD MN)
• Infectious Diseases Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by Technology (USD MN)
• PCR Market Sales by Geography (USD MN)
• In-Situ Hybridization Market Sales by Geography (USD MN)
• Immunohistochemistry Market Sales by Geography (USD MN)
• Sequencing Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.